MX391724B - Nuevos derivados de triazolo[4,5-d]pirimidina. - Google Patents

Nuevos derivados de triazolo[4,5-d]pirimidina.

Info

Publication number
MX391724B
MX391724B MX2019009100A MX2019009100A MX391724B MX 391724 B MX391724 B MX 391724B MX 2019009100 A MX2019009100 A MX 2019009100A MX 2019009100 A MX2019009100 A MX 2019009100A MX 391724 B MX391724 B MX 391724B
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
new triazolo
triazolo
new
sup
Prior art date
Application number
MX2019009100A
Other languages
English (en)
Other versions
MX2019009100A (es
Inventor
Atsushi Kimbara
Mark Rogers-Evans
Matthias Nettekoven
Stephan Roever
Sébastien Schmitt
Uwe Grether
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019009100A publication Critical patent/MX2019009100A/es
Publication of MX391724B publication Critical patent/MX391724B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la formula (I): (Ver Fórmula) en la que de R1 a R4 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
MX2019009100A 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina. MX391724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13183385 2013-09-06
PCT/EP2014/068640 WO2015032769A1 (en) 2013-09-06 2014-09-03 Novel triazolo[4,5-d]pyrimidine derivatives

Publications (2)

Publication Number Publication Date
MX2019009100A MX2019009100A (es) 2019-09-16
MX391724B true MX391724B (es) 2025-03-21

Family

ID=49111076

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009100A MX391724B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2016002117A MX367084B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016002117A MX367084B (es) 2013-09-06 2014-09-03 Nuevos derivados de triazolo[4,5-d]pirimidina.

Country Status (31)

Country Link
US (1) US9593123B2 (es)
EP (3) EP3041843B1 (es)
JP (1) JP6441356B2 (es)
KR (3) KR102454344B1 (es)
CN (1) CN105555788B (es)
AR (1) AR097553A1 (es)
AU (1) AU2014317229B2 (es)
CA (1) CA2915766C (es)
CL (1) CL2016000495A1 (es)
CR (1) CR20160076A (es)
DK (2) DK3483163T3 (es)
EA (1) EA028335B1 (es)
ES (2) ES2714094T3 (es)
HR (2) HRP20190361T1 (es)
HU (2) HUE041760T2 (es)
IL (1) IL243092B (es)
LT (2) LT3483163T (es)
MA (1) MA38826B1 (es)
MX (2) MX391724B (es)
MY (1) MY191628A (es)
PE (2) PE20191528A1 (es)
PH (1) PH12016500250B1 (es)
PL (2) PL3483163T3 (es)
PT (2) PT3483163T (es)
RS (2) RS62234B1 (es)
SG (1) SG11201601714UA (es)
SI (2) SI3483163T1 (es)
TR (1) TR201900662T4 (es)
TW (1) TWI705966B (es)
UA (1) UA116395C2 (es)
WO (1) WO2015032769A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162630A1 (en) * 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CA2960794A1 (en) 2014-11-07 2016-05-12 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN109232694A (zh) * 2015-11-06 2019-01-18 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
JP7090036B2 (ja) 2016-06-23 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー 新規な[1,2,3]トリアゾロ[4,5-d]ピリミジン誘導体
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
CR20220661A (es) * 2016-06-23 2023-02-21 Hoffmann La Roche NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)
JP7090037B2 (ja) * 2016-06-23 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー 新規な[1,2,3]トリアゾロ[4,5-d]ピリミジン誘導体
CN106478639B (zh) * 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432247B (zh) * 2016-09-27 2018-06-29 郑州大学 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用
CN106432248B (zh) * 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN106928296A (zh) * 2017-02-06 2017-07-07 上海华升生物科技有限公司 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法
CN106928235A (zh) * 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN107033148B (zh) * 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN109516990B (zh) * 2017-09-19 2021-06-01 天津药物研究院有限公司 嘧啶并三氮唑类化合物、其制备方法和用途
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用
CN119912457B (zh) * 2025-03-03 2025-10-10 郑州大学 嘧啶并三氮唑类化合物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011643A1 (en) 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US20060128708A1 (en) * 2004-06-17 2006-06-15 The Regents Of The University Of California Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2008141239A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9271962B2 (en) 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
HRP20180466T1 (hr) 2011-10-27 2018-07-27 Lek Pharmaceuticals D.D. Sinteza spojeva triazolopirimidina
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft カンナビノイド受容体2アゴニストとしての新規アダマンチル誘導体
ES2643058T3 (es) 2012-12-07 2017-11-21 F. Hoffmann-La Roche Ag Piridina-2-amidas útiles como agonistas de CB2
LT2928881T (lt) 2012-12-07 2018-06-11 F. Hoffmann-La Roche Ag Nauji piridino dariniai
SG11201504475QA (en) 2012-12-07 2015-07-30 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
WO2014086807A1 (en) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Novel pyrazine derivatives as cb2 receptor agonists
CN105143220B (zh) 2013-03-07 2018-06-22 豪夫迈·罗氏有限公司 吡唑衍生物
HRP20181141T1 (hr) 2013-05-02 2018-09-21 F. Hoffmann - La Roche Ag Derivati purina kao agonisti cb2 receptora
BR112015027394A8 (pt) 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
CN105283452B (zh) 2013-06-11 2019-01-04 豪夫迈·罗氏有限公司 四唑酮衍生物

Also Published As

Publication number Publication date
MA38826A1 (fr) 2016-05-31
CL2016000495A1 (es) 2016-10-07
MY191628A (en) 2022-07-04
KR20210074404A (ko) 2021-06-21
CR20160076A (es) 2016-04-01
HRP20190361T1 (hr) 2019-04-05
TW201542551A (zh) 2015-11-16
AU2014317229A1 (en) 2016-01-07
LT3041843T (lt) 2019-03-12
KR20160050061A (ko) 2016-05-10
PH12016500250B1 (en) 2019-09-13
HUE041760T2 (hu) 2019-05-28
CA2915766A1 (en) 2015-03-12
EA028335B1 (ru) 2017-11-30
KR20220140651A (ko) 2022-10-18
PT3041843T (pt) 2019-02-26
EP3041843A1 (en) 2016-07-13
PT3483163T (pt) 2021-08-24
HRP20211322T1 (hr) 2021-11-26
PE20160691A1 (es) 2016-07-28
RS58390B1 (sr) 2019-04-30
MX2019009100A (es) 2019-09-16
PH12016500250A1 (en) 2016-05-16
WO2015032769A1 (en) 2015-03-12
ES2714094T3 (es) 2019-05-27
RS62234B1 (sr) 2021-09-30
CN105555788B (zh) 2018-11-23
AR097553A1 (es) 2016-03-23
US9593123B2 (en) 2017-03-14
US20160168158A1 (en) 2016-06-16
DK3041843T3 (en) 2019-03-25
KR102454344B1 (ko) 2022-10-14
SG11201601714UA (en) 2016-04-28
TWI705966B (zh) 2020-10-01
PL3483163T3 (pl) 2021-11-22
HUE055201T2 (hu) 2021-11-29
MX367084B (es) 2019-08-05
DK3483163T3 (da) 2021-08-30
MX2016002117A (es) 2016-07-05
PE20191528A1 (es) 2019-10-23
SI3483163T1 (sl) 2021-11-30
PL3041843T3 (pl) 2019-06-28
ES2883923T3 (es) 2021-12-09
UA116395C2 (uk) 2018-03-12
EP3483163B1 (en) 2021-06-23
EP3483163A2 (en) 2019-05-15
JP6441356B2 (ja) 2018-12-19
MA38826B1 (fr) 2016-12-30
EA201690478A1 (ru) 2016-06-30
CA2915766C (en) 2023-09-26
LT3483163T (lt) 2021-09-10
IL243092A0 (en) 2016-02-01
NZ756513A (en) 2021-05-28
EP3483163A3 (en) 2019-07-24
JP2016532707A (ja) 2016-10-20
TR201900662T4 (tr) 2019-02-21
EP3943497A1 (en) 2022-01-26
SI3041843T1 (sl) 2019-04-30
HK1219277A1 (zh) 2017-03-31
AU2014317229B2 (en) 2018-11-08
CN105555788A (zh) 2016-05-04
NZ715085A (en) 2021-05-28
IL243092B (en) 2019-06-30
EP3041843B1 (en) 2019-01-02
KR102349567B1 (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
PH12016500250A1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
PH12015501843A1 (en) Novel pyrazol derivatives
EA201591064A1 (ru) Новые производные пиридина
PH12015501933A1 (en) Novel pyridine derivatives
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
PH12015502118A1 (en) Pyridin-4-yl derivatives
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
MY180050A (en) Novel purine derivatives
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
EA201591819A1 (ru) Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
MX2015016766A (es) Nuevos derivados de tetrazolona.
CO7200259A2 (es) Nuevos derivados de piridina